BIOS 5.52 Bioscrip Inc $BIOS Hit a 52 week low of 5.44 Closing the day 11/06/14 at 5.52 -0.72 -11.54% With a day low of 5.44 and a total volume of 4,661,988.
BIOS Recent Posts: http://investorshangout.com/BioScrip-Inc-BIOS-53498/
BIOS Bioscrip Inc Recent Headline News
BioScrip (BIOS) Stock Lower Today After Third Quarter Earnings Results
at The Street - Thu Nov 06, 12:24PM CST
Shares of BioScrip (BIOS) are down after the company reported a net loss of $28.3 million for the 2014 third quarter.
BIOS: 5.52 (-0.72)
BioScrip Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 05, 3:35PM CST
BioScrip®, Inc. (NASDAQ: BIOS) (the "Company"
today announced its financial results for the third quarter of 2014. Third quarter revenue from continuing operations was $244.0 million and the net loss from continuing operations, net of income taxes, was $37.6 million or a loss of $0.55 per basic and diluted share. Non-GAAP adjusted loss from continuing operations per basic and diluted share was $0.42.
BIOS: 5.52 (-0.72)
Downtrend Call Working As BioScrip Stock Falls 10.1% (BIOS)
Comtex SmarTrend(R) - Wed Oct 29, 11:05AM CDT
SmarTrend identified a Downtrend for BioScrip (NASDAQ:BIOS) on September 23rd, 2014 at $7.20. In approximately 1 month, BioScrip has returned 10.09% as of today's recent price of $6.47.
BIOS: 5.52 (-0.72)
BioScrip To Host Third Quarter 2014 Earnings Call
PR Newswire - Wed Oct 22, 3:30PM CDT
BioScrip®, Inc. (NASDAQ: BIOS) announced today that the Company will release its 2014 third quarter financial results on Wednesday, November 5, 2014, after the market closes. The Company will host a conference call at 8:30 a.m. Eastern Standard Time (EST) on Thursday, November 6, 2014. Richard Smith, President and Chief Executive Officer, and Hai Tran, Chief Financial Officer, will conduct the call.
BIOS: 5.52 (-0.72)
BioScrip Has Returned 15.8% Since SmarTrend Recommendation (BIOS)
Comtex SmarTrend(R) - Wed Oct 22, 9:55AM CDT
SmarTrend identified a Downtrend for BioScrip (NASDAQ:BIOS) on September 23rd, 2014 at $7.20. In approximately 4 weeks, BioScrip has returned 15.77% as of today's recent price of $6.06.
BIOS: 5.52 (-0.72)
BioScrip Down 18.7% Since SmarTrend Downtrend Call (BIOS)
Comtex SmarTrend(R) - Wed Oct 15, 9:36AM CDT
SmarTrend identified a Downtrend for BioScrip (NASDAQ:BIOS) on September 23rd, 2014 at $7.20. In approximately 3 weeks, BioScrip has returned 18.69% as of today's recent price of $5.85.
BIOS: 5.52 (-0.72)
BioScrip's Infusion Services Strong, Bottom Line Dwindles - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 12:40PM CDT
On Sep 30, we issued an updated research report on Bioscrip, Inc. (BIOS) ??? provider of home infusion and pharmacy benefit management (PBM) services.
EW: 123.57 (+2.47), CVS: 88.43 (+0.93), BIOS: 5.52 (-0.72), HOLX: 26.58 (+0.12)
Bioscrip Home Infusion Unit Could be an M&A Remedy
at The Street - Thu Sep 04, 8:33AM CDT
Bioscrip has been divesting assets for a year now, but the health services company could find itself a target for both large strategic and financial players.
BIOS: 5.52 (-0.72), CVX: 118.53 (+1.48), WAG: 66.65 (+0.99)
BioScrip (BIOS) in Focus: Stock Adds 8.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:46AM CDT
BioScrip (BIOS) was a big mover last session, with shares rising over 8% on the day.
RTIX: 5.07 (+0.07), PRXL: 53.50 (+0.64), BIOS: 5.52 (-0.72), ICLR: 52.27 (+0.38)
BioScrip Posts Wider-than-Expected Q2 Loss on Poor Margins - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 12:50PM CDT
BioScrip, Inc. (BIOS) recently declared its second-quarter 2014 results.
ABAX: 53.84 (-0.61), BIOS: 5.52 (-0.72), ALR: 40.07 (-0.13), HSP: 56.64 (+3.54)
BioScrip Reports Second Quarter 2014 Financial Results
PR Newswire - Wed Aug 06, 3:30PM CDT
BioScrip, Inc. (NASDAQ: BIOS) today announced its financial results for the second quarter of 2014. Second quarter revenue from continuing operations was $247.1 million, and the net loss from continuing operations, net of income taxes, was $18.6 million, or $0.27 per basic and diluted share. Non-GAAP adjusted loss from continuing operations per basic and diluted share was $0.07.
BIOS: 5.52 (-0.72)
BioScrip To Host Second Quarter 2014 Earnings Call
PR Newswire - Wed Jul 23, 3:30PM CDT
BioScrip®, Inc. (NASDAQ: BIOS) announced today that the Company will release its 2014 second quarter financial results on Wednesday, August 6, 2014, after the market closes.
BIOS: 5.52 (-0.72)
BioScrip Appoints Thomas Pettit As Senior Vice President And Chief Operating Officer
PR Newswire - Fri Jul 18, 7:30AM CDT
BioScrip, Inc. (NASDAQ: BIOS) (the "Company" today announced that Thomas F. Pettit has been appointed as Senior Vice President and Chief Operating Officer, effective immediately. Mr. Pettit will succeed Richard Jenkins, a Managing Director at Alvarez & Marsal, who had served as BioScrip's Interim Chief Operating Officer since November 2013. To ensure a smooth transition, Mr. Jenkins will continue as a consultant to the Company for a short period of time. Mr. Pettit will report to Rick Smith, the Company's President and Chief Executive Officer.
BIOS: 5.52 (-0.72)
BioScrip's PBM Services Continue to Suffer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 6:10PM CDT
On Jul 10, we issued an updated research report on Bioscrip, Inc. (BIOS).
ISRG: 508.65 (+3.28), MASI: 25.48 (+0.75), BIOS: 5.52 (-0.72), HOLX: 26.58 (+0.12)
BioScrip Completes Sale of Home Health Services Business to LHC Group
PR Newswire - Tue Apr 01, 6:06AM CDT
BioScrip®, Inc. (NASDAQ: BIOS) today announced that it has completed the previously announced sale of substantially all of its Home Health business, known as Deaconess HomeCare, to LHC Group, Inc. (NASDAQ: LHCG). The transaction represents a total deal value of approximately $60 million. BioScrip intends to use the net proceeds from the sale to pay down a portion of its outstanding debt.
LHCG: 23.75 (+0.12), BIOS: 5.52 (-0.72)
LHC Group Completes Acquisition of Deaconess HomeCare
GlobeNewswire - Tue Apr 01, 6:03AM CDT
LHC Group Inc. (Nasdaq:LHCG), a national provider of home health, hospice and comprehensive post-acute healthcare services, announced today that it has completed the previously announced transaction with BioScrip(R), Inc. (Nasdaq:BIOS) to purchase two of its operating subsidiaries, doing business as Deaconess HomeCare and Elk Valley Health Services, for $59.5 million. The transaction adds 32 agencies in four states, increasing LHC Group's geographical footprint to 340 post-acute care agencies across 26 states, and is anticipated to be accretive to LHC Group's 2014 earnings by between $0.05 and $0.10 per diluted share.
LHCG: 23.75 (+0.12), BIOS: 5.52 (-0.72)
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
ABAX: 53.84 (-0.61), AFOP: 13.72 (+0.42), BIOS: 5.52 (-0.72), ASEI: 54.47 (-0.87), ATRC: 16.85 (+0.18)
BioScrip Now in Strong Sell Territory - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 3:05PM CST
On Mar 4, 2014, Zacks Investment Research downgraded BioScrip to a Zacks Rank #5 (Strong Sell).
HLF: 39.99 (+0.21), CVS: 88.43 (+0.93), BIOS: 5.52 (-0.72), RAD: 5.35 (+0.16)
Weakness Seen in BioScrip (BIOS) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:36AM CST
BioScrip has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
AAP: 145.56 (-3.81), CBK: 6.74 (+0.07), BIOS: 5.52 (-0.72), BKS: 22.36 (+0.57)
BioScrip Down on Q4 Loss, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:30AM CST
BioScrip recently declared its fourth-quarter 2013 results.
HLF: 39.99 (+0.21), ABMD: 31.66 (-0.05), BIOS: 5.52 (-0.72), ANGO: 16.85 (+0.10)
BIOS Recent Posts: http://investorshangout.com/BioScrip-Inc-BIOS-53498/
BIOS Bioscrip Inc Recent Headline News
BioScrip (BIOS) Stock Lower Today After Third Quarter Earnings Results
at The Street - Thu Nov 06, 12:24PM CST
Shares of BioScrip (BIOS) are down after the company reported a net loss of $28.3 million for the 2014 third quarter.
BIOS: 5.52 (-0.72)
BioScrip Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 05, 3:35PM CST
BioScrip®, Inc. (NASDAQ: BIOS) (the "Company"
today announced its financial results for the third quarter of 2014. Third quarter revenue from continuing operations was $244.0 million and the net loss from continuing operations, net of income taxes, was $37.6 million or a loss of $0.55 per basic and diluted share. Non-GAAP adjusted loss from continuing operations per basic and diluted share was $0.42. BIOS: 5.52 (-0.72)
Downtrend Call Working As BioScrip Stock Falls 10.1% (BIOS)
Comtex SmarTrend(R) - Wed Oct 29, 11:05AM CDT
SmarTrend identified a Downtrend for BioScrip (NASDAQ:BIOS) on September 23rd, 2014 at $7.20. In approximately 1 month, BioScrip has returned 10.09% as of today's recent price of $6.47.
BIOS: 5.52 (-0.72)
BioScrip To Host Third Quarter 2014 Earnings Call
PR Newswire - Wed Oct 22, 3:30PM CDT
BioScrip®, Inc. (NASDAQ: BIOS) announced today that the Company will release its 2014 third quarter financial results on Wednesday, November 5, 2014, after the market closes. The Company will host a conference call at 8:30 a.m. Eastern Standard Time (EST) on Thursday, November 6, 2014. Richard Smith, President and Chief Executive Officer, and Hai Tran, Chief Financial Officer, will conduct the call.
BIOS: 5.52 (-0.72)
BioScrip Has Returned 15.8% Since SmarTrend Recommendation (BIOS)
Comtex SmarTrend(R) - Wed Oct 22, 9:55AM CDT
SmarTrend identified a Downtrend for BioScrip (NASDAQ:BIOS) on September 23rd, 2014 at $7.20. In approximately 4 weeks, BioScrip has returned 15.77% as of today's recent price of $6.06.
BIOS: 5.52 (-0.72)
BioScrip Down 18.7% Since SmarTrend Downtrend Call (BIOS)
Comtex SmarTrend(R) - Wed Oct 15, 9:36AM CDT
SmarTrend identified a Downtrend for BioScrip (NASDAQ:BIOS) on September 23rd, 2014 at $7.20. In approximately 3 weeks, BioScrip has returned 18.69% as of today's recent price of $5.85.
BIOS: 5.52 (-0.72)
BioScrip's Infusion Services Strong, Bottom Line Dwindles - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 12:40PM CDT
On Sep 30, we issued an updated research report on Bioscrip, Inc. (BIOS) ??? provider of home infusion and pharmacy benefit management (PBM) services.
EW: 123.57 (+2.47), CVS: 88.43 (+0.93), BIOS: 5.52 (-0.72), HOLX: 26.58 (+0.12)
Bioscrip Home Infusion Unit Could be an M&A Remedy
at The Street - Thu Sep 04, 8:33AM CDT
Bioscrip has been divesting assets for a year now, but the health services company could find itself a target for both large strategic and financial players.
BIOS: 5.52 (-0.72), CVX: 118.53 (+1.48), WAG: 66.65 (+0.99)
BioScrip (BIOS) in Focus: Stock Adds 8.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:46AM CDT
BioScrip (BIOS) was a big mover last session, with shares rising over 8% on the day.
RTIX: 5.07 (+0.07), PRXL: 53.50 (+0.64), BIOS: 5.52 (-0.72), ICLR: 52.27 (+0.38)
BioScrip Posts Wider-than-Expected Q2 Loss on Poor Margins - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 12:50PM CDT
BioScrip, Inc. (BIOS) recently declared its second-quarter 2014 results.
ABAX: 53.84 (-0.61), BIOS: 5.52 (-0.72), ALR: 40.07 (-0.13), HSP: 56.64 (+3.54)
BioScrip Reports Second Quarter 2014 Financial Results
PR Newswire - Wed Aug 06, 3:30PM CDT
BioScrip, Inc. (NASDAQ: BIOS) today announced its financial results for the second quarter of 2014. Second quarter revenue from continuing operations was $247.1 million, and the net loss from continuing operations, net of income taxes, was $18.6 million, or $0.27 per basic and diluted share. Non-GAAP adjusted loss from continuing operations per basic and diluted share was $0.07.
BIOS: 5.52 (-0.72)
BioScrip To Host Second Quarter 2014 Earnings Call
PR Newswire - Wed Jul 23, 3:30PM CDT
BioScrip®, Inc. (NASDAQ: BIOS) announced today that the Company will release its 2014 second quarter financial results on Wednesday, August 6, 2014, after the market closes.
BIOS: 5.52 (-0.72)
BioScrip Appoints Thomas Pettit As Senior Vice President And Chief Operating Officer
PR Newswire - Fri Jul 18, 7:30AM CDT
BioScrip, Inc. (NASDAQ: BIOS) (the "Company"
today announced that Thomas F. Pettit has been appointed as Senior Vice President and Chief Operating Officer, effective immediately. Mr. Pettit will succeed Richard Jenkins, a Managing Director at Alvarez & Marsal, who had served as BioScrip's Interim Chief Operating Officer since November 2013. To ensure a smooth transition, Mr. Jenkins will continue as a consultant to the Company for a short period of time. Mr. Pettit will report to Rick Smith, the Company's President and Chief Executive Officer. BIOS: 5.52 (-0.72)
BioScrip's PBM Services Continue to Suffer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 6:10PM CDT
On Jul 10, we issued an updated research report on Bioscrip, Inc. (BIOS).
ISRG: 508.65 (+3.28), MASI: 25.48 (+0.75), BIOS: 5.52 (-0.72), HOLX: 26.58 (+0.12)
BioScrip Completes Sale of Home Health Services Business to LHC Group
PR Newswire - Tue Apr 01, 6:06AM CDT
BioScrip®, Inc. (NASDAQ: BIOS) today announced that it has completed the previously announced sale of substantially all of its Home Health business, known as Deaconess HomeCare, to LHC Group, Inc. (NASDAQ: LHCG). The transaction represents a total deal value of approximately $60 million. BioScrip intends to use the net proceeds from the sale to pay down a portion of its outstanding debt.
LHCG: 23.75 (+0.12), BIOS: 5.52 (-0.72)
LHC Group Completes Acquisition of Deaconess HomeCare
GlobeNewswire - Tue Apr 01, 6:03AM CDT
LHC Group Inc. (Nasdaq:LHCG), a national provider of home health, hospice and comprehensive post-acute healthcare services, announced today that it has completed the previously announced transaction with BioScrip(R), Inc. (Nasdaq:BIOS) to purchase two of its operating subsidiaries, doing business as Deaconess HomeCare and Elk Valley Health Services, for $59.5 million. The transaction adds 32 agencies in four states, increasing LHC Group's geographical footprint to 340 post-acute care agencies across 26 states, and is anticipated to be accretive to LHC Group's 2014 earnings by between $0.05 and $0.10 per diluted share.
LHCG: 23.75 (+0.12), BIOS: 5.52 (-0.72)
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
ABAX: 53.84 (-0.61), AFOP: 13.72 (+0.42), BIOS: 5.52 (-0.72), ASEI: 54.47 (-0.87), ATRC: 16.85 (+0.18)
BioScrip Now in Strong Sell Territory - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 3:05PM CST
On Mar 4, 2014, Zacks Investment Research downgraded BioScrip to a Zacks Rank #5 (Strong Sell).
HLF: 39.99 (+0.21), CVS: 88.43 (+0.93), BIOS: 5.52 (-0.72), RAD: 5.35 (+0.16)
Weakness Seen in BioScrip (BIOS) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:36AM CST
BioScrip has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
AAP: 145.56 (-3.81), CBK: 6.74 (+0.07), BIOS: 5.52 (-0.72), BKS: 22.36 (+0.57)
BioScrip Down on Q4 Loss, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:30AM CST
BioScrip recently declared its fourth-quarter 2013 results.
HLF: 39.99 (+0.21), ABMD: 31.66 (-0.05), BIOS: 5.52 (-0.72), ANGO: 16.85 (+0.10)
